莱沃多巴诱导的动力障碍:N-甲基-D-酸受体与神经炎症之间的相互作用
Fanshi Zhang1, Mei Liu1, Jinmei Tuo1
1Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Frontiers in immunology
|October 20, 2023
概括
神经炎症通过调节N-甲基-D-酸受体 (NMDARs) 来促进帕金森病中的Levodopa诱导的运动障碍 (LID). 针对神经炎症和NMDARs可能为LID提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,用乐伏多巴 (L-DOPA) 治疗.
- 治疗L-DOPA可能导致Levodopa诱导的动力障碍 (LID),显著影响患者的生活质量.
- 导致LID病变的确切机制尚不清楚,这阻碍了有效的治疗开发.
研究的目的:
- 通过N-甲基-D-酸受体 (NMDAR) 调节,审查神经炎症在调解LID发展中的作用.
- 评估抗炎药物和NMDAR抗体在缓解LID方面的潜力.
- 为LID的新疗法目标提供理论基础.
主要方法:
- 文献综述侧重于神经炎症,NMDARs和LID之间的相互作用.
- 对LID.中突触可塑性和谷氨酸信号传递现有研究的分析.
- 评估针对神经炎症和NMDARs的潜在治疗干预措施.
主要成果:
- 谷氨酸 (Glu) 介导的突触可塑性变化在LID中至关重要.
- 神经炎症可以调节NMDAR的活性和表达,可能有助于LID.
- 有证据表明,在LID形成过程中,神经炎症和NMDAR之间存在共同调节.
结论:
- 神经炎症通过NMDAR调节在LID发展中发挥着关键作用.
- 抗炎药物和NMDAR对抗剂在缓解LID方面表现有前途.
- 准中央神经炎症和NMDARs为LID提供了潜在的新治疗途径.
相关概念视频
01:24Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:15Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
350
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
350
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
305
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
305